Novel Plaque Enriched Long Noncoding RNA in Atherosclerotic Macrophage Regulation (PELATON).


Journal

Arteriosclerosis, thrombosis, and vascular biology
ISSN: 1524-4636
Titre abrégé: Arterioscler Thromb Vasc Biol
Pays: United States
ID NLM: 9505803

Informations de publication

Date de publication:
03 2020
Historique:
pubmed: 13 12 2019
medline: 15 7 2020
entrez: 13 12 2019
Statut: ppublish

Résumé

Long noncoding RNAs (lncRNAs) are an emergent class of molecules with diverse functional roles, widely expressed in human physiology and disease. Although some lncRNAs have been identified in cardiovascular disease, their potential as novel targets in the prevention of atherosclerosis is unknown. We set out to discover important lncRNAs in unstable plaque and gain insight into their functional relevance. Approach and Results: Analysis of RNA sequencing previously performed on stable and unstable atherosclerotic plaque identified a panel of 47 differentially regulated lncRNAs. We focused on LINC01272, a lncRNA upregulated in unstable plaque previously detected in inflammatory bowel disease, which we termed PELATON (plaque enriched lncRNA in atherosclerotic and inflammatory bowel macrophage regulation). Here, we demonstrate that PELATON is highly monocyte- and macrophage-specific across vascular cell types, and almost entirely nuclear by cellular fractionation (90%-98%). In situ hybridization confirmed enrichment of PELATON in areas of plaque inflammation, colocalizing with macrophages around the shoulders and necrotic core of human plaque sections. Consistent with its nuclear localization, and despite containing a predicted open reading frame, PELATON did not demonstrate any protein-coding potential in vitro. Functionally, knockdown of PELATON significantly reduced phagocytosis, lipid uptake and reactive oxygen species production in high-content analysis, with a significant reduction in phagocytosis independently validated. Furthermore, CD36, a key mediator of phagocytic oxLDL (oxidized low-density lipoprotein) uptake was significantly reduced with PELATON knockdown. PELATON is a nuclear expressed, monocyte- and macrophage-specific lncRNA, upregulated in unstable atherosclerotic plaque. Knockdown of PELATON affects cellular functions associated with plaque progression.

Identifiants

pubmed: 31826651
doi: 10.1161/ATVBAHA.119.313430
pmc: PMC7043732
doi:

Substances chimiques

CD36 Antigens 0
CD36 protein, human 0
RNA, Long Noncoding 0
Reactive Oxygen Species 0

Types de publication

Comparative Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

697-713

Subventions

Organisme : British Heart Foundation
ID : RG/16/10/32375
Pays : United Kingdom
Organisme : British Heart Foundation
ID : FS/17/50/33061
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/S001743/1
Pays : United Kingdom
Organisme : British Heart Foundation
ID : PG/16/51/32180
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0701127
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/K015710/1
Pays : United Kingdom
Organisme : British Heart Foundation
ID : RG/14/3/30706
Pays : United Kingdom
Organisme : British Heart Foundation
ID : CH/09/002/26360
Pays : United Kingdom

Commentaires et corrections

Type : CommentIn

Références

Arterioscler Thromb Vasc Biol. 2010 Mar;30(3):620-7
pubmed: 20056914
J Am Coll Cardiol. 2008 Apr 1;51(13):1258-65
pubmed: 18371555
Nat Rev Genet. 2009 Mar;10(3):155-9
pubmed: 19188922
Eur Heart J. 2010 Mar;31(6):659-66
pubmed: 20159880
Circulation. 2016 May 24;133(21):2050-65
pubmed: 27052414
Arterioscler Thromb Vasc Biol. 2000 May;20(5):1262-75
pubmed: 10807742
Arterioscler Thromb Vasc Biol. 2017 May;37(5):e41-e52
pubmed: 28446473
BMC Genomics. 2014 Jun 10;15:460
pubmed: 24917243
Cell Cycle. 2017 May 3;16(9):815-816
pubmed: 28319435
Lipids Health Dis. 2014 Feb 07;13:27
pubmed: 24502419
Front Physiol. 2018 Nov 22;9:1655
pubmed: 30524312
Circulation. 2012 Sep 11;126(11 Suppl 1):S81-90
pubmed: 22965997
Nat Med. 2014 Apr;20(4):368-76
pubmed: 24584117
Circ Res. 2014 Sep 12;115(7):668-77
pubmed: 25035150
J Proteomics. 2013 Dec 16;95:89-92
pubmed: 23603108
EMBO J. 2014 May 2;33(9):981-93
pubmed: 24705786
J Am Coll Cardiol. 2017 Jul 4;70(1):1-25
pubmed: 28527533
BMC Biol. 2013 May 30;11:59
pubmed: 23721193
J Am Heart Assoc. 2012 Dec;1(6):e003376
pubmed: 23316322
Circ Res. 2014 Jan 31;114(3):434-43
pubmed: 24255059
Nat Biotechnol. 2011 Nov 13;30(1):99-104
pubmed: 22081020
Circ Res. 2019 Aug 16;125(5):535-551
pubmed: 31339449
Cell. 2015 Feb 12;160(4):595-606
pubmed: 25640239
Bioinformatics. 2011 Jul 1;27(13):i275-82
pubmed: 21685081
Adv Immunol. 1997;65:1-46
pubmed: 9238507
Cardiovasc Res. 1999 Feb;41(2):334-44
pubmed: 10341833
Nat Rev Genet. 2011 Nov 18;12(12):861-74
pubmed: 22094949
J Hum Genet. 2006;51(12):1087-1099
pubmed: 17066261
Trends Genet. 2015 May;31(5):239-51
pubmed: 25869999
Circ Res. 2014 May 9;114(10):1569-75
pubmed: 24663402
Circ Res. 2016 Feb 19;118(4):531-4
pubmed: 26892955
Dev Cell. 2008 Aug;15(2):261-71
pubmed: 18694565
Mol Med Rep. 2018 Feb;17(2):2195-2202
pubmed: 29207070
Circ Res. 2016 Feb 19;118(4):535-46
pubmed: 26892956
Science. 2010 Jun 18;328(5985):1570-3
pubmed: 20466885
Nat Med. 2018 Mar;24(3):304-312
pubmed: 29431742
Trends Mol Med. 2015 May;21(5):307-18
pubmed: 25771097
Mol Ther. 2016 May;24(5):978-90
pubmed: 26898221
Cardiovasc Res. 2007 Feb 1;73(3):470-80
pubmed: 17084825
Cell Mol Neurobiol. 2017 Jan;37(1):29-36
pubmed: 26886754
J Am Coll Cardiol. 2012 Jul 24;60(4):290-9
pubmed: 22813605
Nucleic Acids Res. 2005 Jan 14;33(1):439-47
pubmed: 15653644
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Nucleic Acids Res. 2017 Jul 3;45(W1):W12-W16
pubmed: 28521017
EMBO Rep. 2001 Nov;2(11):986-91
pubmed: 11713189
Front Pharmacol. 2019 May 14;10:463
pubmed: 31139076
Cell Death Dis. 2018 May 22;9(6):607
pubmed: 29789536
Nucleic Acids Res. 2013 Apr 1;41(6):e74
pubmed: 23335781
Cardiovasc Res. 1999 Feb;41(2):345-60
pubmed: 10341834
PLoS One. 2015 Dec 31;10(12):e0145930
pubmed: 26720041
Front Genet. 2018 Apr 25;9:144
pubmed: 29922328
Stroke. 2011 Sep;42(9):2556-63
pubmed: 21817153
Eur Heart J. 2016 Nov 7;37(42):3232-3245
pubmed: 27523477
Nat Rev Genet. 2015 Jul;16(7):421-33
pubmed: 26077373

Auteurs

John Hung (J)

From the Centre for Cardiovascular Science, University of Edinburgh, United Kingdom (J.H., J.P.S., A.D.M., J.R., M.B., J.K., K.L.C., R.B., D.E.N., J.C.S., A.H.B.).

Jessica P Scanlon (JP)

From the Centre for Cardiovascular Science, University of Edinburgh, United Kingdom (J.H., J.P.S., A.D.M., J.R., M.B., J.K., K.L.C., R.B., D.E.N., J.C.S., A.H.B.).

Amira D Mahmoud (AD)

From the Centre for Cardiovascular Science, University of Edinburgh, United Kingdom (J.H., J.P.S., A.D.M., J.R., M.B., J.K., K.L.C., R.B., D.E.N., J.C.S., A.H.B.).

Julie Rodor (J)

From the Centre for Cardiovascular Science, University of Edinburgh, United Kingdom (J.H., J.P.S., A.D.M., J.R., M.B., J.K., K.L.C., R.B., D.E.N., J.C.S., A.H.B.).

Margaret Ballantyne (M)

From the Centre for Cardiovascular Science, University of Edinburgh, United Kingdom (J.H., J.P.S., A.D.M., J.R., M.B., J.K., K.L.C., R.B., D.E.N., J.C.S., A.H.B.).

Margaux A C Fontaine (MAC)

Maastricht University Medical Center, Maastricht, the Netherlands (M.A.C.F., L.T., E.A.L.B., J.C.S., A.H.B.).

Lieve Temmerman (L)

Maastricht University Medical Center, Maastricht, the Netherlands (M.A.C.F., L.T., E.A.L.B., J.C.S., A.H.B.).

Jakub Kaczynski (J)

From the Centre for Cardiovascular Science, University of Edinburgh, United Kingdom (J.H., J.P.S., A.D.M., J.R., M.B., J.K., K.L.C., R.B., D.E.N., J.C.S., A.H.B.).

Katie L Connor (KL)

From the Centre for Cardiovascular Science, University of Edinburgh, United Kingdom (J.H., J.P.S., A.D.M., J.R., M.B., J.K., K.L.C., R.B., D.E.N., J.C.S., A.H.B.).

Raghu Bhushan (R)

From the Centre for Cardiovascular Science, University of Edinburgh, United Kingdom (J.H., J.P.S., A.D.M., J.R., M.B., J.K., K.L.C., R.B., D.E.N., J.C.S., A.H.B.).

Erik A L Biessen (EAL)

Maastricht University Medical Center, Maastricht, the Netherlands (M.A.C.F., L.T., E.A.L.B., J.C.S., A.H.B.).

David E Newby (DE)

From the Centre for Cardiovascular Science, University of Edinburgh, United Kingdom (J.H., J.P.S., A.D.M., J.R., M.B., J.K., K.L.C., R.B., D.E.N., J.C.S., A.H.B.).

Judith C Sluimer (JC)

From the Centre for Cardiovascular Science, University of Edinburgh, United Kingdom (J.H., J.P.S., A.D.M., J.R., M.B., J.K., K.L.C., R.B., D.E.N., J.C.S., A.H.B.).
Maastricht University Medical Center, Maastricht, the Netherlands (M.A.C.F., L.T., E.A.L.B., J.C.S., A.H.B.).

Andrew H Baker (AH)

From the Centre for Cardiovascular Science, University of Edinburgh, United Kingdom (J.H., J.P.S., A.D.M., J.R., M.B., J.K., K.L.C., R.B., D.E.N., J.C.S., A.H.B.).
Maastricht University Medical Center, Maastricht, the Netherlands (M.A.C.F., L.T., E.A.L.B., J.C.S., A.H.B.).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH